Published in Vaccine on September 25, 2010
Protection against tuberculosis in Eurasian wild boar vaccinated with heat-inactivated Mycobacterium bovis. PLoS One (2011) 1.11
A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med (2012) 1.09
Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev (2014) 1.03
Vaccine against tuberculosis: what's new? BMC Infect Dis (2014) 0.88
Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis (2012) 0.84
Auditory impairments in HIV-infected individuals in Tanzania. Ear Hear (2014) 0.84
Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma. Hum Vaccin Immunother (2013) 0.76
Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis. J Infect Dis (2013) 0.76
Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis. PLoS One (2016) 0.75
Current status of new tuberculosis vaccine in children. Hum Vaccin Immunother (2016) 0.75
Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA (1994) 14.96
Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 9.66
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Global epidemiology of tuberculosis. Lancet (2006) 6.70
The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics (1995) 4.72
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet (2010) 4.71
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis (2004) 4.26
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med (1999) 3.45
Advances in tuberculosis vaccine strategies. Nat Rev Microbiol (2006) 2.75
Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med (2010) 2.64
BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics (1961) 2.44
Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis (2008) 2.26
Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA (2004) 2.25
Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis (1998) 2.17
Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun (1997) 1.95
Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med (2008) 1.91
Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS (2010) 1.76
Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment? Clin Infect Dis (2004) 1.68
Lipoarabinomannans: from structure to biosynthesis. Biochimie (2003) 1.62
Infection with Mycobacterium avium-intracellulare and the protective effects of Bacille Calmette-Guérin. J Infect Dis (1982) 1.53
Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet (2008) 1.52
Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine (1997) 1.46
Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine (2005) 1.44
Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology (1998) 1.44
Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun (1997) 1.41
BCG vaccination in tuberculous households. Am Rev Respir Dis (1961) 1.40
A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis (2008) 1.39
Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol (2002) 1.29
Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect Immun (2005) 1.25
A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. Tuberculosis (Edinb) (2008) 1.21
New vaccines for the prevention of tuberculosis. Clin Infect Dis (2002) 1.15
BCG vaccination of Indian infants in Saskatchewan. Tubercle (1949) 1.12
HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine. J Infect Dis (2009) 1.12
Results of BCG immunization in New York City. Am Rev Tuberc (1946) 1.06
Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis (2010) 1.00
Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med (2000) 0.98
Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS (2003) 0.97
The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur Respir J (2003) 0.96
Biology of the mycobacterioses. Identification of the tuberculous-infected by skin tests. Ann N Y Acad Sci (1968) 0.96
Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc (1948) 0.89
Duration of protection against tuberculosis conferred by BCG vaccination in infancy. Arch Dis Child (1989) 0.89
Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. BMC Infect Dis (2009) 0.87
Community study of the relative impact of HIV-1 and HIV-2 on intrathoracic tuberculosis. AIDS (2002) 0.85
Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis (2000) 0.84
Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model. Immunology (2001) 0.79
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
Tuberculosis. N Engl J Med (2013) 4.75
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother (2003) 3.83
Endothelial function in HIV-infected persons. Clin Infect Dis (2006) 3.80
Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis (2004) 2.83
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med (2010) 2.73
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. AIDS (2004) 2.45
A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst (2009) 2.40
Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis (2012) 2.38
Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med (2011) 2.36
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med (2006) 2.33
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis (2008) 2.29
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol (2005) 2.19
HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr (2005) 2.13
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis (2011) 2.07
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS (2010) 1.76
Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS One (2011) 1.71
Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med (2010) 1.69
Sample preparation of Gram-positive bacteria for identification by matrix assisted laser desorption/ionization time-of-flight. J Microbiol Methods (2002) 1.56
Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol (2010) 1.56
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine (2006) 1.48
Use of a population-based survey to describe the health of Boston public housing residents. Am J Public Health (2007) 1.47
Multilocus sequence typing of Campylobacter jejuni isolates from humans, chickens, raw milk, and environmental water in Quebec, Canada. J Clin Microbiol (2008) 1.46
Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med (2006) 1.45
A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol (2009) 1.42
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS (2012) 1.40
Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood (2009) 1.40
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine (2011) 1.37
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis (2013) 1.37
Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine (2005) 1.37
Reliable identification of mycobacterial species by PCR-restriction enzyme analysis (PRA)-hsp65 in a reference laboratory and elaboration of a sequence-based extended algorithm of PRA-hsp65 patterns. BMC Microbiol (2008) 1.35
Campylobacteriosis, Eastern Townships, Quebec. Emerg Infect Dis (2004) 1.35
The Southern African Centre for infectious disease surveillance: a one health consortium. Emerg Health Threats J (2013) 1.35
A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2012) 1.33
The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. Drug Alcohol Depend (2008) 1.33
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine (2005) 1.33
Environmental risk factors for infection with Mycobacterium avium complex. Am J Epidemiol (2006) 1.31
Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother (2004) 1.30
Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS (2003) 1.28
Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol (2013) 1.27
Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One (2012) 1.26
Treatment of Tuberculosis. N Engl J Med (2015) 1.25
Comparison of two expert-based assessments of diesel exhaust exposure in a case-control study: programmable decision rules versus expert review of individual jobs. Occup Environ Med (2012) 1.25
Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS (2008) 1.25
Clinical and epidemiological correlates of genotypes within the Mycobacterium avium complex defined by restriction and sequence analysis of hsp65. J Clin Microbiol (2002) 1.15
Comparison of algorithm-based estimates of occupational diesel exhaust exposure to those of multiple independent raters in a population-based case-control study. Ann Occup Hyg (2012) 1.15
A first insight into the genetic diversity of Mycobacterium tuberculosis in Dar es Salaam, Tanzania, assessed by spoligotyping. BMC Microbiol (2006) 1.15
New vaccines for the prevention of tuberculosis. Clin Infect Dis (2002) 1.15
Integration of a participatory research strategy into a rural health survey. J Gen Intern Med (2003) 1.14
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis (2002) 1.14
Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis (2008) 1.14
Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health (2008) 1.14
Human immunodeficiency virus infection in a rural community in the United States. Am J Epidemiol (2004) 1.12
Blood culture contamination in Tanzania, Malawi, and the United States: a microbiological tale of three cities. J Clin Microbiol (2006) 1.12
Diabetes, glycemic control, and risk of tuberculosis: a population-based case-control study. Diabetes Care (2011) 1.11
Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis (2004) 1.11
History of incarceration and gang involvement are associated with recent sexually transmitted disease/HIV diagnosis in African American men. J Acquir Immune Defic Syndr (2008) 1.09
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis (2013) 1.09
The bacteraemia of disseminated tuberculosis among HIV-infected patients with prolonged fever in Tanzania. Scand J Infect Dis (2011) 1.07
Identification of a novel peptidoglycan hydrolase CwlM in Mycobacterium tuberculosis. Biochim Biophys Acta (2004) 1.05
Hepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health (2008) 1.05
Antimicrobial resistance in human and animal pathogens in Zambia, Democratic Republic of Congo, Mozambique and Tanzania: an urgent need of a sustainable surveillance system. Ann Clin Microbiol Antimicrob (2013) 1.03
Tuberculosis in HIV voluntary counselling and testing centres in Dar es Salaam, Tanzania. Scand J Infect Dis (2010) 1.01